We have attached herewith financial results for the quarter ended June 30, 2026.
Kindly take the same on your record.
Thank you.
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 30 Jul 2026, 11:56 AM IST · BSE ID: 064de455-d26f-4d75-9da7-9986ee4708be
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its latest quarterly financial results and approved plans to fully acquire two other companies.
🤖 AI Summary
- Standalone Profit After Tax for Anlon Healthcare was Rs. 479.71 Lakhs for the quarter ended June 30, 2026.
- Standalone Revenue from Operations was Rs. 3,097.56 Lakhs for Q1 FY27, compared to Rs. 3,329.72 Lakhs in Q1 FY26.
- Total Standalone Income stood at Rs. 3,103.52 Lakhs for the quarter ended June 30, 2026.
- Board authorized share swap to acquire 32.52% of Apiqo Organics and 43.33% of Bizotic LifeScience, making them wholly owned subsidiaries.
- Anlon Healthcare Limited was listed on BSE and NSE on September 3, 2025.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue From Operations (Q1 FY27)
3,097.56 Rs. in Lakhs
-6.97%
Standalone Profit/(loss) after tax (Q1 FY27)
479.71 Rs. in Lakhs
35.25%
Basic Earnings per equity share (Q1 FY27)
0.09 Rs.
0.00%
Apiqo Organics Pvt Ltd Acquisition Target
32.52% shareholding
Bizotic LifeScience Pvt Ltd Acquisition Target
43.33% shareholding
🏢 How This Affects the Company
The acquisition authorization for Apiqo Organics Private Limited and Bizotic LifeScience Private Limited aims to integrate these entities as wholly owned subsidiaries, potentially expanding Anlon Healthcare's operational scope or product offerings.
The proposed share swap arrangement for acquisitions, in lieu of cash, will result in the issuance and allotment of fresh equity shares by Anlon Healthcare, impacting share capital and potentially dilution for existing shareholders.
Consolidating Apiqo Organics and Bizotic LifeScience as wholly owned subsidiaries could streamline operations and integration across the group, if executed.
The share swap arrangement introduces potential dilution risk for existing shareholders due to the issuance of new equity shares for consideration other than cash.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders will be affected by the issuance and allotment of fresh equity shares on a preferential basis for the share swap arrangement, which could lead to dilution of existing shareholding.
🔍
Management Signal
The management's decision to pursue full acquisition of Apiqo Organics and Bizotic LifeScience indicates a strategy for consolidation and increased control over related entities.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Board meeting updates on the share swap arrangement and acquisition completion.
Disclosure of full details regarding the preferential allotment of shares for the acquisition.
Q2 FY27 financial results to assess revenue trends and profitability.
MEDIUM RISK
Revenue decline and potential dilution from share swap for acquisitions are identified risks.
💡 Investor Takeaway
Anlon Healthcare reported standalone Profit After Tax of Rs. 479.71 Lakhs for Q1 FY27, an increase from Rs. 354.69 Lakhs in Q1 FY26. Standalone Revenue from Operations for the quarter was Rs. 3,097.56 Lakhs. The Board approved a share swap to acquire remaining stakes in Apiqo Organics and Bizotic LifeScience.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Profit After Tax increased to Rs. 479.71 Lakhs for Q1 FY27 from Rs. 354.69 Lakhs in Q1 FY26, indicating year-over-year profitability growth.
- The company is moving to consolidate two entities, Apiqo Organics and Bizotic LifeScience, into wholly owned subsidiaries, enhancing control over group companies.
⚠️ Concerns
- Standalone Revenue from Operations decreased to Rs. 3,097.56 Lakhs in Q1 FY27 from Rs. 3,329.72 Lakhs in Q1 FY26, a decline of 6.97%.
- Changes in inventories of finished goods, Stock in Trade and work in progress showed a negative value of -789.16 Lakhs for Q1 FY27, compared to -537.18 Lakhs in Q1 FY26.
📅 Company Track Record
Anlon Healthcare Limited was listed on both BSE (Scrip Code: 544497) and NSE (Scrip Code: AHCL) on September 3, 2025. This indicates a limited public track record, with the Q1 FY27 results representing one of the initial quarterly disclosures post-listing.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Anlon Healthcare's standalone Profit After Tax for Q1 FY27?
Anlon Healthcare's standalone Profit After Tax was Rs. 479.71 Lakhs for the quarter ended June 30, 2026.
What was Anlon Healthcare's standalone Revenue from Operations in Q1 FY27?
The standalone Revenue from Operations for Anlon Healthcare in Q1 FY27 was Rs. 3,097.56 Lakhs.
What acquisitions did Anlon Healthcare's Board approve?
The Board approved the acquisition of 32.52% shareholding in Apiqo Organics Private Limited and 43.33% shareholding in Bizotic LifeScience Private Limited via a share swap arrangement.
How will the acquisitions be financed by Anlon Healthcare?
The acquisitions will be financed through the issuance and allotment of fresh equity shares of Anlon Healthcare Limited on a preferential basis for consideration other than cash, to the selling shareholders.
When was Anlon Healthcare Limited listed on the stock exchanges?
Anlon Healthcare Limited was listed on both BSE and NSE on September 3, 2025.
Questions based on this BSE filing only. For information purposes.